Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Enrolling by invitation × Etoposide × Lymphoid × Clear all

Phase

Status

Completed 258 Unknown 64 Terminated 44 Active not recruiting 36 Recruiting 28 Withdrawn 14 Suspended 1 Not yet recruiting 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

Lenalidomide 2 Cyclophosphamide 2 ibrutinib 1 fludarabine 1 Vincristine 1 Ropivacaine 1 Rituximab 1 R-CHOP protocol 1 Prednisone 1 Nivolumab 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Maintenance 1 Magnetic Resonance Spectroscopy 1 Leukapheresis 1 JNJ-64619178 1 JNJ-64264681 1 Inosine Monophosphate 1 Fluorodeoxyglucose F18 1 Fluorescein 1 Etoposide 1 Educational Status 1 Doxorubicin 1 Decitabine 1 Brentuximab Vedotin 1 Blood Specimen Collection 1 Biopsy, Fine-Needle 1 Bendamustine Hydrochloride 1 Angptl4 protein, mouse 1 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07258680 2025-12-02

BrEto-TCL

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Enrolling by invitation

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡